Ultragenyx Pharmaceutical Inc. (RARE) News

Ultragenyx Pharmaceutical Inc. (RARE): $47.94

-0.61 (-1.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RARE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 393

in industry

Filter RARE News Items

RARE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RARE News Highlights

  • For RARE, its 30 day story count is now at 47.
  • Over the past 24 days, RARE's stories per day has been in a clear downtrend, falling by about 1.79 per 4 days.
  • BEAT and ORIC are the most mentioned tickers in articles about RARE.

Latest RARE News From Around the Web

Below are the latest news stories about Ultragenyx Pharmaceutical Inc that investors may wish to consider to help them evaluate RARE as an investment opportunity.

Analysts Predict Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) To Reach $186.00 In 12 Months

In last trading session, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw 0.35 million shares changing hands with its beta currently measuring 1.69. Company’s recent per share price level of $67.45 trading at -$0.37 or -0.55% at ring of the bell on the day assigns it a market valuation of $4.72B. That closing price of RARE’s stock is … Analysts Predict Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) To Reach $186.00 In 12 Months Read More »

Marketing Sentinel | February 26, 2022

J.P. Morgan Says Buy These 2 Stocks as They Are Oversold

2022 has started out with a marked increase in market volatility, accompanied by a sharp reversal of last year’s bullish trend. The sudden correction, and the shift to a more downbeat investor sentiment, are generally attributed to a series of increased risk factors. On the international front, these tensions include geopolitical tensions on the Russia-Ukraine border and around China’s belligerence. Domestically, factors impacting the markets include the inflation that is both high and rising; a

Yahoo | February 17, 2022

Ultragenyx Pharmaceutical Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 11, 2022

Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

Yahoo | February 11, 2022

Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 10, 2022

Ultragenyx Pharmaceutical GAAP EPS of -$1.79 misses by $0.44, revenue of $83.4M misses by $0.28M (NASDAQ:RARE)

Ultragenyx Pharmaceutical press release (RARE): Q4 GAAP EPS of -$1.79 misses by $0.44.Revenue of $83.4M (-8.9% Y/Y) misses by $0.28M.The company expects 2022 revenue for Crysvita

Seeking Alpha | February 10, 2022

Ultragenyx (RARE) Reports Q4 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -35.61% and 0.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 10, 2022

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories1 of $192.6 million 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million Strong Dojolvi® launch continues with approximately 270 patients on reimbursed commercial therapy in the United States as of the end of 2021 Year-end 2021 cash balance of approximately $1.0 billion NOVATO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ultr

Yahoo | February 10, 2022

Ultragenyx Pharmaceutical Q4 2021 Earnings Preview (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) is scheduled to announce Q4 earnings results on Thursday, February 10th, after market close.The consensus EPS Estimate is -$1.19 (-221.6% Y/Y)…

Seeking Alpha | February 9, 2022

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update

NOVATO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, February 10, 2022, at 5:00 pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2021.

GlobeNewswire | February 3, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.756 seconds.